dCK1α-2 is an orally active CK1α molecular glue degrader that targets p53 pathway-related targets. dCK1α-2 exhibits anti-tumor efficacy in mouse models and can increase the expression of p53-related genes. [1].
References:
[1]. Huang L, et al. Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy. JACS Au. 2024 Nov 8;4(11):4423-4434.
References:
[1]. Huang L, et al. Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy. JACS Au. 2024 Nov 8;4(11):4423-4434.
















